

Viral Innate Immune Evasion and the Pathogenesis of Emerging RNA Virus Infections

Tessa Nelemans¹ and Marjolein Kikkert^{1,*}

¹Department of Medical Microbiology, Leiden University Medical Center, Leiden, 2333 ZA, The Netherlands

*Correspondence: m.kikkert@lumc.nl

Abstract

Positive-sense single-stranded RNA (+ssRNA) viruses comprise many (re-)emerging human pathogens that pose a public health problem. Our innate immune system and in particular the interferon response form the important first line of defense against these viruses. Given their genetic flexibility, these viruses have therefore developed multiple strategies to evade the innate immune response in order to optimize their replication capacity. Already many molecular mechanisms of innate immune evasion by +ssRNA viruses have been identified. However, research addressing the effect of host innate immune evasion on the pathology caused by the viral infection is less prevalent in literature, though very relevant and interesting. Since interferons have been implicated in inflammatory diseases and immunopathology in addition to their protective role in infection, the influence of antagonizing the immune response may have an ambiguous effect on the clinical outcome of the viral disease. Therefore, this review discusses what is currently known about the role of interferons and host immune evasion in the pathogenesis of emerging viruses belonging to the coronaviruses, alphaviruses and flaviviruses.

Keywords: positive-sense single-stranded RNA viruses; innate immune evasion; type I and III interferons; viral pathogenesis

Introduction

The positive-sense single-stranded RNA viruses (+ssRNA) comprise many pathogens that are a serious threat to human health. These viruses affect millions of people worldwide and for many of them no treatment is available. Human +ssRNA viruses that currently have a large impact on public health include dengue virus (DENV), and the more recent (re-)emerging viruses such as chikungunya virus (CHIKV) and Zika virus (ZIKV) [1]. Although Middle East Respiratory Syndrome-coronavirus (MERS-CoV) does not infect large numbers of people like the afore-mentioned viruses, 35% of diagnosed patients die of MERS [2], and considering the virus' genetic possibilities, any change that increases transmissibility between humans would mean a serious public health threat that is considered worth preparing for. Gaining insight into the pathogenesis of these viruses is thus relevant to thoroughly understand them, and identify new treatment and prevention options.

Our innate immune system is the first line of defense against invading pathogens. It has developed multiple mechanisms to sense invading viruses and subsequent signal transduction pathways are targeted at the initial containment of the infection in the body. Conserved microbial structures, known as pathogen-associated molecular patterns (PAMPs), can be sensed by pattern recognition receptors (PRRs) of the innate immune system, resulting in the activation of downstream signaling pathways that then elicit an effective antimicrobial response [3]. Interferons are key molecules in this response. There are three families of interferons of which the type I and III IFNs are regarded as the main effectors during the antiviral innate response in many different cell types, while type II IFNs are more specifically expressed by specialized immune cells, and are involved in the modulation of adaptive immunity. Both type I and III IFNs activate the so-called "interferon stimulated genes" (ISGs), which promote an antiviral state in the infected as well as in neighboring cells, restrict viral replication, and induce apoptosis to protect the organism from virus spread [4,5]. Therefore, in order to create a window-of-opportunity for efficient replication despite the innate immune system, +ssRNA viruses have developed multiple mechanisms to prevent IFN induction and subsequent signaling. Viral innate immune evasion strategies have been shown to target PRRs, downstream signaling molecules and transcription factors of the IFN pathway, as well as its effector ISG products [6,7].

One of the reasons why the +ssRNA viruses are causing pathology in humans is probably this ability to evade the innate immune system and in particular the IFN response. The targeting of the interferon response by the +ssRNA viruses has been quite extensively reviewed [6-12]. The strategies of viral proteins to suppress IFN signaling are thus well established, although the diversity in the strategies used suggests that further research will most probably identify yet different evasion mechanisms. Importantly, most of these reviewed studies are dominated by *in vitro* experiments and/or they examined ectopically expressed proteins to determine the role of viral factors in innate immune evasion. The actual link between host innate immune evasion and the pathology observed during viral infection generally receives less attention and therefore remains to be comprehensively investigated [13]. In order to set the stage, we will here review and discuss the available data on this latter subject. We will discuss viral proteins targeting innate immunity from emerging viruses belonging to the Togaviridae, Coronaviridae and Flaviviridae families, and summarize the available knowledge on the influence of these viral activities on the pathogenesis of the virus infections. The main focus of this review will be on describing

the evasion of the type I and type III IFN response and their influence on infection outcome based on advances from studies conducted *ex vivo* or *in vivo*.

Innate immune response to positive-sense single-stranded RNA viruses

During viral infections the type I and III IFNs are rapidly induced to initiate the antiviral state. The type I IFN family consists of 13 subtypes of IFN α (in humans), one subtype of IFN β and several subtypes that are poorly studied (IFN κ , IFN ϵ , IFN τ , IFN δ , IFN ω and IFN ζ) [5,14]. The more recently discovered type III IFN system consists of IFN- λ 1, IFN- λ 2, IFN- λ 3 and IFN- λ 4 [5]. The trigger for type I and III IFN production and the downstream signaling molecules are actually similar for the two types [15,16]. However, type III interferons preferentially act on epithelial cells providing antiviral protection locally, and are thought to cause less immune-mediated damage than the more potent, systemic type I IFN response [17-19]. Therefore, it is now proposed that type III IFNs are an initial response to knock down infection at the epithelial barriers without causing immunopathology, while type I IFNs come into play when this first line of defense is not sufficient to control the infection [18]. The production of these two types of IFNs is initiated when the innate immune system recognizes invading viruses through its PRRs. Three types of PRRs have been well-described in sensing RNA viruses: the Toll-like receptors (TLRs), nucleotide-binding oligomerization domain(NOD)-like receptors (NLRs) and retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs)[20]. Specifically, the activation of the IFN response through TLR3, TLR7 and the RLRs RIG-I and melanoma differentiation-associated protein 5 (MDA5) is well-studied [3,20].

TLR3 is activated by dsRNA and upon activation it will signal through TRIF (TIR-domain-containing adapter-inducing interferon- β), which results in the induction of the following four transcription factors: activator protein 1 (AP-1), nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B), and interferon regulator factors 3 and 7 (IRF3 and IRF7). These four transcription factors are all involved in the regulation of IFN expression, while only NF- κ B and AP-1 are involved in the induction of pro-inflammatory cytokines [21]. The activation of the first two transcription factors is achieved by the recruitment of the receptor-interacting protein 1 (RIP1) and TNF receptor-associated factors 2 and 6 (TRAF2/6). This pathway ultimately leads to the degradation of the inhibitor of κ B ($\text{I}\kappa\text{B}$) and thereby the release of NF- κ B. The activation of the other two transcription factors is achieved by signaling through TRAF3, which activates two kinases: TRAF family member-associated NF- κ B activator binding kinase 1 (TBK1) and inducible $\text{I}\kappa\text{B}$ kinase ϵ (IKK ϵ). Active TBK1 and IKK ϵ can phosphorylate IRF3 and IRF7 to promote their translocation to the nucleus [3,20,21]. TLR7, which is located in the endosomes, recognizes ssRNA and signals through the myeloid differentiation primary response gene 88 (MyD88) pathway. MyD88 forms a complex with interleukin-1 receptor-associated kinases 1 and 4 (IRAK-4 and IRAK-1) and TRAF6. Next, this complex can activate the transcription factor IRF7 [3,20,21] (Figure 1A).

RIG-I and MDA5 can sense viral molecules in the cytoplasm. RIG-I exposes its caspase activation and recruitment domains (CARD) upon binding of short RNAs containing 5'-triphosphate ends and polyuridine-rich sequences [22]. The CARD can bind to the adaptor protein mitochondrial antiviral signaling (MAVS), which interacts with TRAF3 and TRAF2/6, thereby converging on the TLR3 pathways. The binding of RIG-I to MAVS is further promoted by polyubiquitination of the CARD domain and subsequent tetramerisation of RIG-I. As described above, TRAF3 triggers TBK1 and IKK ϵ to phosphorylate

IRF3 and IRF7, after which the transcription factors translocate to the nucleus. Signaling via TRAF2/6 results in the activation of NF- κ B [21,23] (Figure 1A). MDA5 is thought to trigger the same signaling cascade as RIG-I, except that MDA5 is activated by long dsRNA [21-23]. The IRFs are essential for the induction of IFN α/β and IFN λ , while NF- κ B is thought to be required as a co-factor. The expression of the interferons in an early stage is mainly dependent on IRF3, which is constitutively expressed. The IFNs then trigger the transcription of IRF7 which can serve to amplify the IFN response [5,21].




Figure 1: Innate immune response to positive-stranded RNA viruses and IFN signaling. (A) IFN production is induced when ssRNA (TLR7, RIG-I) or dsRNA (TLR3, RIG-I, MDA5) is detected in the cell. Signaling through these PRRs will ultimately result in the translocation of NF- κ B, IRF3 and IRF7 to the nucleus. These transcription factors then initiate production of the IFNs and pro-inflammatory cytokines. (B) The type I IFNs bind to a receptor composed of IFNAR1 and IFNAR2, while the type III IFNs signal through IFNLR1 and IL10RB. The signaling pathways of both types then converge, and result in expression of the interferon stimulated genes (ISGs).

When IFN α/β and IFN λ are induced, they bind to their cognate receptor to induce the expression of ISGs. While IFN α/β bind to a heterodimeric receptor consisting of the subunits IFNAR1 and IFNAR2, IFN λ signals through a heterodimeric receptor composed of IFNLR1 and IL-10 receptor β (IL10RB) [5,24]. Remarkably, both receptors then activate the same signaling cascade; which led to the idea that the type III IFN system might be redundant. Nonetheless, there seems to be some difference in the expression levels and kinetics of the stimulated ISGs, even though the systems share the same signal

transduction pathways [18,25]. Binding to the type I IFN or type III IFN receptor leads to the assembly of the ISG factor 3 (ISGF3) complex. This complex is built up from the heterodimer signal transducer and activator of transcription 1 (STAT1), STAT2, and IRF9. STAT1 and STAT2 heterodimerization is initiated after they have been phosphorylated by Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2). ISGF3 is capable of binding to the IFN-stimulated response elements in the ISG promoter, resulting in the expression of the ISGs that will induce the antiviral state [5,24] (Figure 1B). Together, the ISGs virtually act on every step in the viral life cycle (i.e. entry, replication, translation, assembly and budding) [26].

Similar to the interferons, NF- κ B can regulate the expression of hundreds of genes. NF- κ B regulates genes that are involved in recruitment of innate immune cells and activating the pro-inflammatory state in these cells, and the activation and differentiation of inflammatory T cells [27]. It is for example an important transcription factor for the production of pro-inflammatory cytokines including interleukin 1 β (IL-1 β), IL-6 and tumor necrosis factor α (TNF- α) and chemokines such as IL-8, C-C motif chemokine ligand 2 (CCL2) and C-X-C motif chemokine 10 (CXCL10) [28]. NF- κ B signaling is thus an important mediator in controlling virus infection, but it has also been implicated in inflammatory diseases [29].

Coronaviruses

Genome organization

The human coronaviruses were regarded as low pathogenic for a long time. However, the more recently discovered Severe Acute Respiratory Syndrome CoV (SARS-CoV) and MERS-CoV proved otherwise. The SARS-CoV outbreak in 2002-2003 caused a worldwide epidemic with a global case-fatality rate of around 11% [30]. The MERS-CoV epidemic that started in 2012 is still ongoing with an estimated case-fatality rate of 35% globally [2]. Both of these emerging viruses can cause severe respiratory illness [31-33]. In addition, MERS-CoV can cause renal dysfunction.

The coronaviruses have the largest known positive-stranded RNA genome of around 30kb with a 5' terminal cap and a poly(A) tail at the 3' end [34] (Figure 2). The 5' terminal two-thirds of the genome encode two large open reading frames (ORFs), 1a and 1b. The expression of the viral genome results in the production of two polypeptides (pp1a and pp1ab). The translation of pp1ab is accomplished by a -1 ribosomal frameshift at the end of ORF1a. These polypeptides are then processed by two or three internally virus-encoded proteases into 16 nonstructural proteins (nsp). The nsps are involved in the replication of the viral genome, the subgenomic mRNA synthesis, and also the evasion of host innate immunity [34,35]. The remaining one-third of the genome encodes the viral structural proteins spike (S), envelope (E), membrane (M), and nucleocapsid (N) and accessory proteins. The accessory genes have also been implicated in antagonizing the IFN response. SARS-CoV encodes 8 accessory proteins, while MERS-CoV encodes 5 accessory proteins [36].




Figure 2: Genome organization of SARS-CoV and MERS-CoV. The genome encodes two large open reading frames (ORF1a and ORF1b), which contain the sixteen nonstructural proteins (1 to 16). ORF1b is transcribed after a -1 ribosomal frameshift (gray dot). The structural proteins (S, spike; E, envelop; M, membrane; N, nucleocapsid) and accessory proteins are expressed from subgenomic RNAs. Blue, green and yellow indicate the nonstructural, structural and accessory proteins, respectively.

The role of interferons in coronavirus pathogenesis

The IFN response is considered important for the control of a coronavirus infection. IFN treatments improved outcomes of SARS-CoV and MERS-CoV infection in mice and in non-human primates [37-41]. In human SARS-CoV-infected patients, IFN α therapy in combination with steroids was associated with higher oxygen saturation levels and faster improvement of lung abnormalities [42]. In patients with a MERS-CoV infection, the treatment of IFN α in combination with ribavirin resulted in an improved survival rate at 14 days after diagnosis. However, this effect was not present anymore after 28 days, and other studies concluded that there is no beneficial effect of the used IFN treatments [43-45]. Currently, another trial to study the efficacy of IFN β 1b in combination with lopinavir/ritonavir in MERS patients is still ongoing [46]. Therefore, there is no actual proof of the efficacy of IFN treatment yet. Notwithstanding, the expression levels of IFN during the disease course do suggest that IFN is important. For example, studies with macaques showed that aged macaques infected with SARS-CoV had more severe pathology compared to the young adults, while the induction of IFN β was considerably lower in the aged animals [47]. In two studies with SARS patients, no expression of IFN or ISGs was detected in peripheral blood mononuclear cells derived from the patients indicating that these genes were suppressed [48,49]. In one MERS case with a fatal outcome, RIG-I, MDA5 and IRF3/7 were downregulated compared to the levels of these IFN components in a recovering patient, and additionally no IFN α was produced [50].

Several knockout mice models also illustrate the importance of IFN signaling in the control of a coronavirus infection. STAT1^{-/-} 129 mice, which are completely deficient for type I, II and III IFN signaling, were more susceptible to a mouse-adapted SARS-CoV (rMA15) and the SARS-CoV Urbani strain and showed increased pathology [51,52]. In C57BL/6 mice lacking IFNAR1 or IFNLR1, the replication of the SARS-CoV in the lungs was enhanced, and in double-knockout mice, the viral titers in the lungs were even further increased [53]. Additionally, mice deficient for both IFNAR1 and IFNLR1 or STAT1 showed delayed clearance of rMA15 from the lungs [54]. Remarkably, the IFNAR1^{-/-} mice, IFNLR1^{-/-} [52] and the IFNAR1/IFNLR1 double-knockout mice [54] showed no difference in clinical outcome compared to WT

SARS-CoV-infected mice, while STAT1^{-/-} mice did present with signs of disease and decreased survival [52,54]. This would suggest that the increased replication of SARS-CoV is not directly related to pathology and disease outcome. In addition, these results highlight that an interferon-independent signaling pathway through STAT1 is possibly important in restricting SARS-CoV pathology. Moreover, C57BL/6J mice deficient in MyD88, TRIF or TLR3 showed more weight loss and more severe lung pathology due to SARS-CoV infection [55,56].

Since mice are not naturally susceptible to MERS-CoV, one way to allow MERS-CoV infection is to transduce mice with an adenovirus expressing the human DPP4 receptor [57]. Transduced IFNAR1^{-/-} mice showed increased body weight loss, delayed viral clearance and increased inflammation, but these animals did not die from the MERS-CoV infection. In the same study, transduced MyD88^{-/-} and MAVS^{-/-} mice were infected with MERS-CoV resulting in considerable weight loss in the MyD88^{-/-} group [57]. In summary, these findings from studies in mouse models suggest that the IFN response is important for the clearance and control of the coronaviruses during infection. However, the restriction of viral replication does not always seem to be directly associated with the clinical outcome of the infection.

Paradoxically, there is also clear evidence for an immunopathogenic role of IFN in coronavirus infections. The innate immune response and in particular the elevated levels of pro-inflammatory cytokines have been recognized as possible contributors to the pathology of SARS for a long time [58,59]. High levels of pro-inflammatory cytokines such as IL-1, IL-6 and IFN γ and chemokines such as CCL2, CXCL10 and IL-8 were detected in sera of SARS patients [60-62]. In another cohort of SARS patients, high expression levels of ISGs such as CD58, IFNAR1 and IFNGR1 (interferon gamma receptor 1) and the IFN-stimulated chemokines CXCL10 and CCL2 were correlated with disease severity. Especially, CXCL10 was upregulated during the crisis phase in SARS patients who died. Simultaneously, other ISGs were significantly downregulated in the severe-SARS patients [63]. This is further supported by studies in MERS patients. An upregulation of CXCL10 has also been demonstrated in serum of MERS subjects with pneumonia [64]. Correspondingly, Kim et al. showed that in MERS patients CXCL10 was correlated with severe disease and, in addition to that, its expression was delayed [65]. Moreover, IFN α was found to be associated with severe disease. However, this might be misleading as patients received PEGylated IFN- α 2a, which might affect the detected association [65].

The controversial role of IFN in disease pathogenesis has also been demonstrated in mouse models. In one study, BALB/c mice were infected with SARS-CoV rMA15, and survival and disease severity were measured [38]. BALB/c mice are highly susceptible to this mouse-adapted SARS-CoV, and infection is lethal in young mice [66]. MA15 infection resulted in clear signs of disease in the mice and considerable weight loss, while 85% of the mice had died at 8 d post infection. Importantly, this study showed that the expression of IFN β and other pro-inflammatory cytokines was delayed in these severely ill mice. Moreover, all the BALB/c IFNAR^{-/-} mice infected with MA15 survived, and they only had mild to moderate weight loss and disease scores [38]. In line with that, DeDiego et al. showed that the inhibition of NF- κ B resulted in reduced inflammation and lung pathology in BALB/c mice that were infected with MA15 [67]. Together, these observations indicate that a dysregulated and/or delayed IFN response is at least partly responsible for the pathology of SARS and MERS.

Innate immune evasion and coronavirus pathogenesis

Ambiguously, the IFN response seems to be contributing simultaneously to protection against viruses and to the pathology induced by the same virus infections. Evasion of the IFN response by coronaviruses may thus not necessarily lead to more severe pathology. Many of the nsps, structural proteins and accessory proteins encoded by coronaviruses have been suggested to antagonize the IFN response. Interestingly, it was shown that in cell culture MERS-CoV is more sensitive to IFN α and IFN β treatment than SARS-CoV, which suggests that SARS-CoV is more effective in evading the innate immune response [68,69].

From the structural proteins the role of the E protein in pathogenesis has been studied in particular. DeDiego et al. demonstrated that BALB/c mice infected with MA15 lacking the E protein show reduced lung pathology, they did not suffer considerable weight loss, nor any mortality was observed compared to the wildtype MA15-infected mice. The researchers were able to link this reduced virulence of the SARS-CoV- Δ E to a reduced induction of NF- κ B [67]. This suggests then that the pathogenesis of SARS-CoV is closely linked to the inflammatory response. Furthermore, an additional study showed that the pathogenesis caused by the SARS-CoV E protein is connected to its ion channel (IC) activity. They claim that the IC activity could activate the inflammasome, which would then result in damaging immune responses [70].

The accessory genes 3b and 6 of SARS-CoV have been implicated in antagonizing the IFN pathway [71], while other accessory genes still have unknown functions. However, no convincing evidence on the effect of the accessory proteins on SARS-CoV virulence has been generated yet. One group showed that a SARS-CoV mutant that lacked the genes encoding accessory proteins 6, 7a, 7b, 8a, 8b and 9b did not change the virulence of the virus in transgenic mice expressing human ACE2 [72]. Zhao et al. only showed a minimal effect of the deletion of accessory protein 6 (p6) on the virulence of SARS-CoV; hACE2 transgenic mice survived an additional day when infected with the p6 mutant, and weight loss was delayed [73]. In another study, genes 3, 6 and 7 were shown to be nonessential to viral replication and disease outcome, although the authors used a mouse model that only supports viral replication and does not produce clinical symptoms [74]. In an immunosuppressed Syrian golden hamster model, the deletion of the accessory gene 7 from SARS-CoV had no influence on morbidity and mortality compared to hamsters with a wildtype infection [75]. In contrast, MERS-CoV accessory genes have been shown to influence coronavirus replication and disease outcome in mice. This was evaluated in a mouse model that was made susceptible to MERS-CoV by modulating DDP4 with CRISPR (288-330^{+/+} mice) [76]. MERS-CoV with a complete deletion of genes 3, 4a, 4b, and 5 replicated less efficiently in the lungs of these mice. Removing the accessory genes 3-5 from a mouse-adapted MERS-CoV, which can cause clinical symptoms, prevented weight loss of the mice and reduced the production of pro-inflammatory cytokines such as IL-6, TNF α and CCL2 [77]. Moreover, using a chimeric mouse hepatitis virus expressing MERS-CoV accessory protein 4b, it was established in primary mouse bone marrow-derived macrophages (BMM) that protein 4b is necessary for optimal replication of the virus. Moreover, the chimeric virus with a mutation in the 4b catalytic site could replicate to equivalent titers as wildtype virus in RNase L^{-/-} BMM and RNase L^{-/-} mice indicating that 4b counteracts the RNaseL pathway and thereby enhances viral replication [78]. In summary, none of the SARS-CoV accessory proteins have been

linked to coronavirus pathogenesis yet. On the contrary, the MERS-CoV accessory proteins have been implicated as major virulence factors, possibly by counteracting IFN induced responses. This difference between the viruses might not be completely surprising since there is no sequence homology between the accessory genes. However, it is surprising that MERS-CoV seems to counteract the innate immune response in more ways than SARS-CoV, since the observed difference in sensitivity to IFN treatment suggests that SARS-CoV is more effective in evading the innate immune response. This however might be explained by the specific IFN pathways that are targeted. For example, SARS-CoV was shown to block STAT1 translocation using p6 [79], while MERS-CoV did not inhibit STAT1 translocation after cells were treated with 1000 ng PEG-IFN ml⁻¹ [68]. Thus, the type of pathways blocked by the different coronaviruses might explain differences in sensitivity to IFNs. However, until we have a complete picture of the evasive activities of each of these viruses we cannot draw firm conclusions on this.

Many of the coronavirus nsps have been implicated in the evasion of innate immunity, but the effect of only a few have been studied *in vivo*. Nsp3 of the coronaviruses encodes a macrodomain, which functions as ADP-ribose-1'-phosphatase. Fehr et al. created SARS-CoV mutants that lack this macrodomain activity, and they infected BALB/c mice with these mutant viruses. Their survival was significantly increased and the mice did not develop lung pathology after infection with viruses lacking the macrodomain activity. Moreover, they found increased expression of type I IFN, ISG15, CXCL10 and the inflammatory cytokines IL-6 and TNF [80]. This is interesting since most studies observed decreases in pro-inflammatory cytokines when survival and disease pathology improved. Remarkably, infection of IFNAR^{-/-} mice did not restore the pathogenesis of the mutant viruses, which might suggest that the type III IFN system or other possibly unknown systems (also) play an important role in SARS pathogenesis [80]. Besides its macrodomain nsp3 also contains the papain-like protease (PL^{pro}) required for the processing of the coronavirus nsps. PL^{pro} is thought to antagonize the IFN response through its deubiquitinating enzyme (DUB) activity, which allows the protease to remove ubiquitin from a substrate. Ubiquitination is a posttranslational modification that, among many other functions, is very important in the regulation of the innate immune pathways [81]. Our group recently tested recombinant MERS-CoV mutants lacking DUB activity, but with intact proteolytic activity, in a lethal mouse model. Transgenic mice expressing human DPP4 which were infected with the DUB-negative MERS-CoV showed significantly increased survival compared to wildtype virus infected mice. Moreover, levels of IFN β , IFN λ and several ISGs and pro-inflammatory cytokines were found to be upregulated at an earlier time point in the mice infected with DUB-negative MERS-CoV than in the wildtype virus infected mice, while late induction of innate immune response in wt virus-infected mice reached an out-of-control high level. This suggests that the DUB-negative MERS-CoV is less effective in evading innate immunity and that the resulting early and balanced immune response is important for controlling the infection, while the delay in innate immune induction caused by the DUB function during wt virus infection dysregulates the response, causing more severe, immunopathological, symptoms [Knaap et al., unpublished data]. In summary, this indicates that the DUB activity of nsp3 is a major contributor to the pathogenesis of coronavirus infections. Altogether, these studies showed that nsp3 has several mechanisms to evade the immune response which causes the pathology of coronaviruses to be enhanced.

Nsp16 has 2'-O-methyltransferase activity and is thereby involved in capping the viral RNA to prevent detection by innate immune sensors. A SARS-CoV nsp16 mutant without its 2'-O-methyltransferase activity was used to infect BALB/c mice. In comparison to wildtype-infected animals, mice generally suffered less weight loss, had less pronounced lung disease and their survival rate was increased. Interestingly, the virus was not attenuated anymore in MDA5 knockout mice and the Interferon-induced protein with tetratricopeptide repeats (IFIT) family knockout mice, while in the IFNAR1^{-/-} mice the pathogenesis of the mutant virus was not completely restored [82]. This again suggests a possible role of type III IFNs or of IFIT, which can recognize unmethylated RNA, and which might act in an IFN-independent manner in the SARS pathogenesis. Moreover, a MERS-CoV nsp16 mutant lacking 2'-O-methyltransferase activity showed attenuated replication in primary human airway epithelial cells and in 288-330^{+/+} mice. The nsp16 mutation in a highly lethal mouse-adapted MERS-CoV rescued the mice and only minimal disease was observed [83]. Together these studies implicate that nsp16 is an important factor in SARS and MERS pathogenesis. The pathogenesis associated with nsp16 seems to be dependent on IFIT and not necessarily the type I IFNs, although for MERS-CoV this was not tested in a mouse model.

In addition to proteins, the coronavirus genome also encodes non-coding RNAs (ncRNAs). The inhibition of a small ncRNA derived from the N gene was associated with decreased inflammation and reduced gross pathology of the lung, though viral titers and survival were not influenced. After pre-treating mice with an inhibitor of the ncRNA-N, the lungs of BALB/c mice infected with MA15 had an increased expression of ISGs (ISG15, MX1) and decreased expression of pro-inflammatory cytokines like IL-6 and CCL2 [84]. This study thereby supports a view in which a dysregulated IFN response and increased inflammation (partly) due to immune evasive activities of the virus are responsible for the lung pathology observed during coronavirus infection.

Alphaviruses

Genome organization

Chikungunya virus is an alphavirus, member of the *Togaviridae* order, which causes fever, skin rash and severe joint pain. The symptoms resolve within weeks, but the arthralgia is recurrent in 30-40% of the cases and can persist for months or years [85]. The virus is transmitted to humans by *Aedes* mosquitoes and currently mainly affects individuals in the Americas.

Alphaviruses have a genome of around 12kb containing a 5' terminal cap and a 3' terminal poly(A) tail (Figure 3). The genome consists of two ORFs; the 5' terminal ORF encodes the nonstructural proteins and the 3' terminal ORF encodes the structural proteins. Consequently, two polyproteins are produced which are cleaved by viral and host proteases into four nsps and five structural proteins (C, E3, E2, 6K, E1). The nsps are expressed from the genomic RNA and are involved in viral replication. The structural proteins are expressed from a subgenomic RNA and are the essential components of the new viral particles [86,87].




Figure 3: Genome organization of alphaviruses. The genome encodes two open reading frames, which contain the four nonstructural proteins (nsP) and the structural proteins (C, capsid; E, envelop). The structural proteins are expressed from a subgenomic promoter (SGP). Blue and green indicate the nonstructural and structural proteins, respectively.

The role of interferons in alphavirus pathogenesis

The IFN response is also implicated in controlling CHIKV infection. Patients infected with CHIKV had high serum levels of IFN α , and the expression level was positively correlated to the viral load [88]. Besides Chikungunya patients, also mice and non-human primates had high levels of type I IFN in their blood after CHIKV infections [89,90]. However, striking differences in immune profile are found in patients during each phase of CHIKV infection. During the acute phase IFN α and several pro-inflammatory cytokines and chemokines peaked, while during the early convalescent phase T cell cytokines were mainly detected. In the chronic phase IL-17, a pro-inflammatory cytokine produced by T cells, is significantly upregulated [91]. In patients with persistent joint pain, and thus more severe disease, high levels of IL-6 were detected [91,92]. Moreover, Teng et al. performed a meta-analysis, in which they demonstrated that a common expression profile of IFN and pro-inflammatory cytokines was found during the acute phase of CHIKV infection in all patient cohorts [93]. Taken together, this suggests that an effective IFN response during the acute phase is responsible for controlling CHIKV.

Treatment with IFN α before infecting mice with CHIKV decreased viremia and disease signs. However, treating the mice on day 3 during the infection did not result in a therapeutic effect anymore [89]. This further supports that during the acute phase the antiviral response is activated by CHIKV and is involved in controlling CHIKV infection, while in later phases this response is not effective either because it is shutting off or is effectively evaded by CHIKV [89]. Moreover, a study in aged macaques showed that CHIKV infection persists in these elderly animals. This was linked to a reduced ISG response; rhesus macaque fibroblasts that were stimulated with serum of aged macaques, collected 3 d post infection, produced lower levels of ISGs than after stimulation with sera from the younger adult animals [94]. On the contrary, persistence of the inflammatory response could also contribute to the pathogenesis of Chikungunya as demonstrated by the high levels of pro-inflammatory cytokines and chemokines in patients with persistent joint pain [91]. In addition, cellular immune components such as macrophages and CD4⁺ T cells have also been implicated in the immunopathology of the disease [95].

The role of innate immunity in CHIKV infection has been extensively studied in experimental animal models. Primary fibroblasts isolated from wildtype and TLR3^{-/-} mice showed that replication of CHIKV was increased in the TLR3^{-/-} cells. Interestingly, high levels of type I IFN were expressed in the TLR3^{-/-} fibroblasts. This suggests that other PRRs activate the IFN response, although this was not sufficient to control replication since replication was enhanced in the TLR3 deficient cells. In TLR3^{-/-} C57BL/6 mice the

viral load was increased, inflammation was more severe and the virus could disseminate more extensively [96]. This is supported by another study that found TRIF^{-/-} mice had an increased viral load and inflammation (foot swelling) compared to wildtype mice infected with CHIKV [97]. However, conflicting results were obtained with TLR3^{-/-} mice in a study by Schilte et al. [88]. They did not observe any changes in viral load in tissue or blood, though Her et al. [96] suggested that this might be related to methodology differences such as the age of the mice and the injection route used. Furthermore, CHIKV infection is not lethal in wildtype immunocompetent C57BL/6 or 129 mice. However, IFNAR^{-/-} and STAT^{-/-} mice do succumb to the infection and the pathology is more severe [88,98,99]. This suggests an important role for IFN in CHIKV pathogenesis. However, it was striking that in one of these studies the wildtype mice did not produce detectable protein levels of type I IFN during infection [88]. Moreover, RIG-I^{-/-}, MDA5^{-/-}, MAVS^{-/-} and MyD88^{-/-} mice infected with CHIKV all survived and only small increases in viral load in serum or tissue were observed. MyD88^{-/-} mice did show a slightly more severe phenotype with dissemination of CHIKV 72 h post infection. The results together probably indicate that several PRRs are involved in sensing CHIKV and that missing one of the receptors is not sufficient to induce a lethal phenotype as seen in the IFNAR^{-/-} mice [88]. In line with this Rudd et al. showed increased viremia in MAVS^{-/-} and MyD88^{-/-} mice [97]. Moreover, in agreement with earlier studies, they showed that IFNAR^{-/-} mice died and had severe pathology (i.e. edema and hemorrhagic shock). In addition, Rudd et al. evaluated the influence of IRF3, IRF7 and IRF3/7 on chikungunya pathology. All IRF3^{-/-} and IRF7^{-/-} mice survived CHIKV infection, while the double knockout mice all died within 6 days. Viral titers in both blood and tissues were significantly higher for the IRF3/7^{-/-} mice compared to wildtype mice. In all three groups of knockout mice disease symptoms occurred earlier and were more severe compared to wildtype mice. Furthermore, in IRF3/7^{-/-} serum high levels of pro-inflammatory cytokines and no IFN α/β was detected. IRF7 was found to be most important for the induction of IFN after CHIKV infection [97]. Lastly, several ISGs have also been shown to influence viral titers in blood or tissues [100-102] or survival [103]. From these different knockout models it can be concluded that the IFN response greatly influences disease control and severity and that CHIKV is sensed dominantly through TLR3, though adaptive immunity has also been shown to contribute to the control of CHIKV infection [104].

Innate immune evasion and alphavirus pathogenesis

CHIKV is thought to evade innate immune responses by causing a transcriptional and translational shut-off in the host cell [105]. Chikungunya infection triggers IFN β and ISG mRNA production that is dependent on IRF3 in primary human fibroblasts. However, no protein is expressed during infection illustrating that CHIKV blocks host cell translation thereby preventing the ISG effector response. Moreover, the authors showed that 24 h post infection transcription is also effectively inhibited [106]. Nsp2 of CHIKV is thought to be involved in mediating the transcriptional host shut-off, although this has only been established in cell lines. For Sindbis virus, a relative of CHIKV, a nsp2 mutant was shown to increase IFN production, and survival of the infected mice was considerably increased [107]. The exact mechanisms of the host translational shut-off and the viral proteins involved are not clear yet and hampers investigating the role of this evasion method in the Chikungunya pathogenesis. In addition, nsp2 of the alphaviruses has been suggested to directly inhibit STAT signaling, even though this has not been investigated in experimental animal models yet [105].

Recently, Chan et al. [108] studied the role of nonstructural protein mutations in CHIKV pathogenesis. A mutation in the nsP1/2 cleavage site (the mutant was called RH) that affects polyprotein processing resulted in reduced viremia; the virus was cleared earlier from the blood and caused reduced inflammation. This also correlated with locally increased IFN α / β and pro-inflammatory cytokines and chemokines levels 15 h post infection. A second mutant with a substitution in the protease domain of nsP2 (mutant EV) actually showed increased viremia and joint inflammation compared to wildtype CHIKV. A double mutant containing both mutations (mutant RHEV) behaved like the RH mutant. Interestingly, wildtype and EV CHIKV showed a delayed induction of inflammatory cytokines and chemokines compared to RH and RHEV virus and 6 d post infection these viruses produced higher levels of pro-inflammatory cytokines like IL-6 and IL-1 than the RH and RHEV mutants [108]. This supports the notion that the antiviral IFN responses affect disease severity and again shows that a dysregulated innate immune response, inflicted by viral immune evasion activities, might contribute to pathology. Overall, CHIKV nsP2 has often been suggested as an important viral factor involved in innate immune evasion and might thus be a major cause of pathology, though this has not yet been confirmed *in vivo*. Therefore, much remains to be discovered about the immune evasion by CHIKV proteins in the context of the viral infection.

Flaviviruses

Genome organization

Flaviviruses comprise human pathogens that are the main cause of arthropod-borne diseases [109]. This review will place emphasis on DENV and the recently emerged ZIKV, since these currently have the largest societal impact. Infections with both these viruses are mainly asymptomatic. Dengue is endemic in many countries from the Americas, Southeast Asia and Africa. There are five distinct serotypes of DENV [110]. Clinical symptoms of Dengue include fever, skin rash and headache and in severe cases will lead to plasma leakage with or without hemorrhage. The disease is mostly self-limiting, but a small proportion of patients will develop severe disease [111,112]. ZIKV is most prevalent in the Americas and in mild cases causes fever, rash, muscle pain and headache. ZIKV can cause neurological complications such as the Guillain–Barré syndrome and ZIKV infection especially during early stages of pregnancy leads to congenital abnormalities such as microcephaly [112,113]. Both ZIKV and DENV are transmitted by the *Aedes* mosquito.

Flaviviruses have a genome of around 11kb containing a 5' terminal cap, but they lack a poly(A) tail (Figure 4). The genome encodes one large polyprotein that is processed by viral and host proteases into the three structural proteins (E, C and prM) and the seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5). The nonstructural proteins are involved in viral replication and modulation of host responses, while the structural proteins comprise the components that are assembled into new viral particles [109].

Flavivirus




Figure 4: Genome organization of flaviviruses. The genome encodes one open reading frame, which contains the seven nonstructural proteins (NS) and the structural proteins (C, capsid; prM, premembrane; E, envelope). Blue and green indicate the nonstructural and structural proteins, respectively.

The role of interferons in flavivirus pathogenesis

The IFN response is upregulated in Zika patients, which suggests that this response is involved in controlling the infection. Zika patients in the acute phase of infection had increased mRNA levels of IFN α , IFN β and IFN γ in their peripheral blood compared to healthy controls, and ZIKV infection was also associated with high mRNA levels of TLR3. In the same study it was found that viral load was positively correlated with type I IFN expression [114]. However, some pro-inflammatory cytokines and IFN stimulated chemokines have been associated with severity of both Zika and Dengue. One study showed that Zika patients with moderate symptoms and viremia had higher levels of IL-1RA, CCL2, CXCL10 and IL-8 than patients with mild symptoms or no viremia [115]. CCL2 and CXCL10 have also been associated with ZIKV-infected women carrying fetuses with congenital abnormalities [116]. In Dengue patients the severity of the disease has been associated with high plasma levels of IL-1RA and CXCL10 [117]. Moreover, severe cases of Dengue with increased levels of pro-inflammatory cytokines such as IL-1 and TNF α , anti-inflammatory cytokine IL-10 and chemokines including IL-8 and CXCL10 have been reported [118-121]. This cytokine storm in dengue patients can lead to the plasma leakage and hemorrhage seen in severe Dengue cases. This implicates that immunopathology is a substantial part of flavivirus pathogenesis.

On the contrary, the importance of interferons in restricting DENV and ZIKV infections is quite clear from mouse models, since only mice lacking innate immune components are susceptible to replication of these flaviviruses. After subcutaneous infection of ZIKV in adult immunocompetent mice, the mice do not show any sign of disease and viral titers are not detected in the blood of these mice. However, A129 mice that lack the type I IFN receptor did show signs of illness and had measurable blood titers. Lethality in A129 mice was shown to be age-dependent. In 3-week-old A129 mice severe disease is observed and all animals succumb to the ZIKV infection, while 5-week-old mice had reduced mortality and 11-week-old A129 mice all survive [122]. In contrast, Dowall et al. showed that 5-6 weeks old A129 mice all die from ZIKV infection [123], although this difference might be explained by the virus strain and dosage. 3-week-old AG129 mice, which are deficient in type I and II IFN signaling, also died after ZIKV infection. No significant differences in mortality rate, weight loss and organ viral titers were found between the A129 and AG129 mice [122]. This indicates that especially the type I IFN response is important in controlling ZIKV infection. However, Aliota et al. showed that both young and adult AG129 succumb to ZIKV infection, which might highlight a role of IFN γ in controlling ZIKV infection in adults [124]. AG129 mice also succumbed to infection with DENV (serotypes 1 and 2), though A129 all survived this infection [125,126]. A129 mice did have disseminated infection of DENV2 [125]. Therefore, in contrast with ZIKV

infection, both type I and II IFN responses appear to be important in restricting DENV infections in mice. IFNAR^{-/-} C57BL/6 mice also died from infection with two mouse-adapted DENV2 strains (D2S10 [127] and D220) and had measurable viral titers in blood and tissues [128]. Blocking of the IFN I receptor with an antibody mimics the phenotype seen in knockout mice. In wildtype C57BL/6 ZIKV-infected mice treatment with the blocking antibody resulted in 40-100% mortality depending on the route of ZIKV injection, and induced severe neuropathology. Comparable with the A129 mice, the blocking antibody also resulted in detectable viral titers in blood and various tissues [129].

In accordance with these observations, flavivirus infection and its control have also been associated with signaling components of the IFN pathways. For example, wildtype C57BL/6 mice were infected intravaginally with ZIKV and it was shown that ZIKV was able to replicate in the lower female reproductive tract. The measured viral load was positively correlated to the induction of IRF7. Moreover, treatment of these mice with acitretin (an enhancer of RIG-I signaling) one day prior to infection, induced type I and III IFNs and pro-inflammatory cytokines, while inhibiting ZIKV replication in the lower female reproductive tract [130]. C57BL/6 mice lacking IFNAR1, MAVS, IRF3, or IRF3/5/7 were inoculated with ZIKV. The IFNAR^{-/-} and the IRF triple knockout mice significantly lost weight and succumbed to disease, although the percentage of surviving mice was strain- and age-dependent. The MAVS^{-/-} and IRF3^{-/-} mice showed no morbidity or mortality [131]. C57BL/6 mice deficient in IRF3 and IRF7 developed viremia, while the wildtype mice did not [132]. Mice deficient in MAVS, TRIF or both (DK) that were infected with ZIKV exhibited no signs of disease or mortality, though the virus was detected in the blood and tissues. The viral titer in the blood and tissues was highest for the DK mice. In addition, the higher viral loads were associated with decreased type I IFN production and IRF7 expression in the spleen [133]. In DENV-infected C57BL/6 mice lacking the MAVS adapter, no mortality was observed either, though viremia was detected and delayed and decreased type I IFN expression in blood and the spleen was observed as was seen with the ZIKV-infected mice [134]. DENV2 infection induces lethality in STAT^{-/-} BALB/c mice [135]. Lastly, a combination of TLR3 and TLR7/8 agonists was shown to protect rhesus macaques against DENV infection by decreasing viremia, though the study groups were very small [136].

The results on the role of type I IFNs in ZIKV pathogenesis during pregnancy are conflicting. There is evidence that links type I IFNs to protection of the placenta and fetus against ZIKV. For example, the mid-gestation placenta is largely resistant to ZIKV infection, and this is associated with higher levels of IFN α , IFN β and IFN λ expression [137]. Moreover, a trans-placental transmission mouse model of ZIKV to study the effect during pregnancy has been developed by knocking out IFNAR1. Using this model both protective and harmful effects of IFN were found. Crossing IFNAR^{-/-} female mice with male wildtype mice results in IFNAR^{+/-} placenta and fetuses. ZIKV infection of these IFNAR^{+/-} mice at E10.5 (mid-pregnancy) did not result in fetal demise and caused reduced damage to the placenta compared to fetuses completely deficient in type I IFN signaling. However, the fetuses still suffered from intrauterine growth retardation [138]. This study mainly suggests that the presence of IFN signaling in the fetuses and placenta had a protective effect. In contrast, when pregnant IFNAR1^{-/-} female mice were mated with wildtype male mice and infected with ZIKV at E6.5 and E7.5, fetal demise occurred in the majority of the cases. The rest of the IFNAR1^{+/-} fetuses exhibited intrauterine growth retardation. Moreover, treating pregnant wildtype mice with an IFNAR1 blocking antibody also resulted in growth retardation, although

to a lesser extent than the IFNAR1^{+/-} fetuses [139]. Yockey et al. [140] additionally showed that IFNAR1^{-/-} fetuses do not undergo fetal demise when the pregnant dams were infected with ZIKV at E5.5. When dams got infected at E8.5 with ZIKV, IFNAR1^{-/-} fetuses showed reduced intrauterine growth retardation compared to the IFNAR1^{+/-} fetuses. Viral titers were comparable to the IFNAR^{+/-} placentas or higher in the IFNAR^{-/-} placentas, indicating that the type I IFN response, and not the virus load, is responsible for a more severe disease phenotype. The authors also examined the effect of the treatment with recombinant IFN β and IFN λ 3 on human chorionic villous isolated from mid-gestation placentas. IFN β treatment resulted in abnormal villous structures, while IFN λ treatment did not influence the villi [140]. Interestingly, there was a huge difference in genes induced by the two types of IFN, although they share the same signaling pathways. The conflicting results in the role of IFN might be partially explained by the differences in embryonic days analysed. It is however clear that the role of type I IFNs in protection of the fetus against ZIKV requires further investigation.

A protective role of type III IFNs in restricting ZIKV during pregnancy has been clearly identified. Primary human placental trophoblasts have been shown to resist ZIKV infection and produce high basal levels of type III IFN [141]. Moreover, two 3D models consisting of primary placental fibroblasts or endothelial cells co-cultured with JEG-3 cells that better reflect primary human trophoblasts were developed. Using these models it was shown that 3D-cultured JEG-3 cells became less susceptible to ZIKV, while expressing high basal levels of IFN λ 1/2 and ISGs. In addition, human placental villi isolated from second-trimester placentas, which are mostly resistant to ZIKV infection, were also capable of producing IFN λ 1 [142]. Furthermore, evidence from mice models also supports a protective role of type III IFNs. Mice deficient in IFNLR1 were mated and the pregnant dams were infected with ZIKV at E12 (embryonic day 12) after pretreatment with an antibody blocking IFNAR1 to allow trans-placental transmission. ZIKV titers in the placenta and fetal heads were higher in IFNLR1 deficient mice and fetuses than the 'wildtype' mice. Interestingly, IFNLR1^{+/-} placentas and fetuses had comparable ZIKV titers to wildtype mice indicating that type III IFN in the placenta and fetus is sufficient to control ZIKV. This is further supported by the fact that pegylated mouse IFN- λ 2 treatment of wildtype mice (pretreated with an IFNAR1 blocking antibody) infected with ZIKV at E12 presented with reduced ZIKV titers in the placenta and in the fetal heads. Furthermore, isolated human chorionic villi, fetal membranes and decidua basalis all responded to IFN λ 1 and IFN λ 3 treatment by inducing ISGs such as OAS1 and had reduced ZIKV titers [143]. A second study also showed the beneficial effects of IFN λ 2 treatment. Treating ZIKV-infected IFNAR^{-/-} pregnant mice with type III IFNs at E10.5 prevented fetal demise and improved fetal growth. In addition, ZIKV titers were reduced in both maternal and fetal organs [138]. Both studies found no beneficial effect of IFN λ treatment early during pregnancy (administered at E5.5 and E6).

Innate immune evasion and flavivirus pathogenesis

In particular the nsps of the flaviviruses are considered antagonists of host innate immunity. NS1 of DENV has been shown to increase pathogenesis in mice. Sublethal doses of DENV2 in combination with recombinant NS1 resulted in lethality in IFNAR^{-/-} mice and NS1 was shown to induce vascular leakage. Moreover, when these mice were vaccinated over 6-weeks with DENV2 NS1 and later challenged with a lethal dose of DENV2, none of the mice died [144]. However, since these results have been obtained in IFNAR^{-/-} mice the link with innate immune evasion cannot be established. The immunocompromised

mouse models currently used will always limit studies addressing dengue pathogenesis in the context of innate immunity and therefore the development of a more adequate animal model is desirable.

DENV NS5 is thought to inhibit IFN signaling by degrading STAT2 [145]. Interestingly, NS5 has been shown to confer host-specificity. For example, NS5 cannot inhibit mouse STAT2 in several cell lines and this is suggested to be one of the main reasons that DENV is not able to replicate in immunocompetent mice. This hypothesis is supported by the fact that STAT2^{-/-} mice led to delayed clearance of DENV [146]. A mouse model with a humanized STAT2 might thus be interesting to study the effect of NS5 and possibly other immune evasion mechanisms on Dengue pathogenesis [146].

The flavivirus NS2B3 complex serves as a protease and can cleave human STING *in vitro* and is thereby thought to inhibit the antiviral immune response and to support viral replication. However, mice deficient in STING (*Tmem173^{gt}*) did not respond any differently to ZIKV infection than wildtype mice [147], which also makes it less likely that NS2B3 will affect Zika pathogenesis through its action on STING. However, NS2B3 might still target other signaling molecules to interfere with the innate immune response.

Another study showed that the inflammasome can decrease the IFN response and support viral replication [148]. This was established using *Nlrp3^{-/-}* neonatal mice (*Nlrp3* plays a role in inflammasome activation) that were injected with ZIKV in the brain. The knockout mice showed higher expression of IFN β , lower viral titers in the brain and they gained more weight than the wildtype mice. In human peripheral mononuclear blood cells it was also shown that *Nlrp3* inhibition increased IFN β expression. The same study showed that NS1 can activate the inflammasome in cell lines [148]. Together, these data suggest that ZIKV NS1 might be able to support viral replication through activation of the inflammasome, but this needs further confirmation.

Xia et al. [149] discovered that ZIKV NS1 can suppress IFN β *in vitro* dependent on the ZIKV strain (FSS13025 or PRVABC-59). NS1 of FSS13025 was not able to suppress IFN β , in contrast to NS1 of PRVABC-59. There was only one amino acid difference between NS1 of the two strains: an A188V substitution. The substitution was shown to be responsible for suppressing IFN β expression in bone marrow-derived dendritic cells (BMDCs) isolated from C57BL/6J mice [149]. Moreover, Xia et al. infected A129 mice with the two strains of ZIKV and also two mutant viruses: FSS13025 A188V and PRVABC-59 V188A. The viruses with an alanine at position 188 in NS1 showed considerably higher levels of IFN β in serum of infected animals. However, survival in neonatal CD-1 mice infected with a mutant virus was not significantly different compared to survival in wt-infected mice [149], suggesting that the effect of NS1 alone is not a significant contributor to the pathogenesis of ZIKV. The same authors demonstrated that NS2A, NS2B, NS4A, NS4B, and NS5 were able to suppress IFN β *in vitro*, which leaves many potential candidates to investigate the virulence of ZIKV.

Conclusions

Although the IFN response is regarded as the first line of defense against viruses, its role in the pathogenesis is double sided. On the one hand, many +ssRNA viruses have developed mechanisms to

antagonize the IFN response to protect themselves against the antiviral effects, and without a proper immune response that restricts virus replication, the infection as well as the disease might progress. On the other hand, viral evasion often causes a delayed, hyper-induced IFN and inflammatory response, which have been shown to cause pathology. Animal models help us to assess the function of the immune evasive viral proteins in the context of virus infection and their clinical outcomes. Conflicting results on the link between IFN pathways and viral pathogenesis remain, which probably emphasize this ambiguous role of innate immune response in pathogenesis. Overall, from these studies we can conclude that a balance and a correct timing of the IFN response seem most important in controlling disease severity. Also the importance of type III IFN in controlling virus infections is becoming more evident as was discussed for ZIKV [12]. Elucidating the role of type III IFN in other viral infections is thus of great interest especially for viruses targeting mucosal surfaces such as MERS-CoV. Moreover, as we gain more knowledge on the interaction between innate immunity and the viral infection including the activities of viral immune evasive proteins, possibilities for the development of novel treatments and prevention strategies might appear on the horizon.

Acknowledgements: This work and publication costs were funded by Leiden University Medical Center via M.K.'s institutional permanent position as an Associate Professor.

Author contributions: T.N. prepared the initial manuscript. M.K. revised the manuscript.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Brechot, C.; Bryant, J.; Endtz, H.; Garry, R.F.; Griffin, D.E.; Lewin, S.R.; Mercer, N.; Osterhaus, A.; Picot, V.; Vahlne, A., et al. 2018 international meeting of the Global Virus Network. *Antiviral Res* **2019**, *163*, 140-148, doi:10.1016/j.antiviral.2019.01.013.
2. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). Available online: [https://www.who.int/news-room/fact-sheets/detail/middle-east-respiratory-syndrome-coronavirus-\(mers-cov\)](https://www.who.int/news-room/fact-sheets/detail/middle-east-respiratory-syndrome-coronavirus-(mers-cov))
3. Akira, S.; Uematsu, S.; Takeuchi, O. Pathogen recognition and innate immunity. *Cell* **2006**, *124*, 783-801, doi:10.1016/j.cell.2006.02.015.
4. Ivashkiv, L.B.; Donlin, L.T. Regulation of type I interferon responses. *Nat Rev Immunol* **2014**, *14*, 36-49, doi:10.1038/nri3581.
5. McNab, F.; Mayer-Barber, K.; Sher, A.; Wack, A.; O'Garra, A. Type I interferons in infectious disease. *Nat Rev Immunol* **2015**, *15*, 87-103, doi:10.1038/nri3787.
6. Beachboard, D.C.; Horner, S.M. Innate immune evasion strategies of DNA and RNA viruses. *Curr Opin Microbiol* **2016**, *32*, 113-119, doi:10.1016/j.mib.2016.05.015.
7. García-Sastre, A. Ten Strategies of Interferon Evasion by Viruses. *Cell Host Microbe* **2017**, *22*, 176-184, doi:10.1016/j.chom.2017.07.012.
8. Chen, S.; Wu, Z.; Wang, M.; Cheng, A. Innate Immune Evasion Mediated by Flaviviridae Non-Structural Proteins. *Viruses* **2017**, *9*, doi:10.3390/v9100291.
9. Uno, N.; Ross, T.M. Dengue virus and the host innate immune response. *Emerg Microbes Infect* **2018**, *7*, 167, doi:10.1038/s41426-018-0168-0.
10. Gokhale, N.S.; Vazquez, C.; Horner, S.M. Hepatitis C Virus. Strategies to Evade Antiviral Responses. *Future Virol* **2014**, *9*, 1061-1075, doi:10.2217/fvl.14.89.

11. Kindler, E.; Thiel, V.; Weber, F. Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response. *Adv Virus Res* **2016**, *96*, 219-243, doi:10.1016/bs.aivir.2016.08.006.
12. Pardy, R.D.; Valbon, S.F.; Richer, M.J. Running interference: Interplay between Zika virus and the host interferon response. *Cytokine* **2019**, *119*, 7-15, doi:10.1016/j.cyto.2019.02.009.
13. Channappanavar, R.; Perlman, S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. *Semin Immunopathol* **2017**, *39*, 529-539, doi:10.1007/s00281-017-0629-x.
14. Li, S.F.; Gong, M.J.; Zhao, F.R.; Shao, J.J.; Xie, Y.L.; Zhang, Y.G.; Chang, H.Y. Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection. *Cell Physiol Biochem* **2018**, *51*, 2377-2396, doi:10.1159/000495897.
15. Onoguchi, K.; Yoneyama, M.; Takemura, A.; Akira, S.; Taniguchi, T.; Namiki, H.; Fujita, T. Viral infections activate types I and III interferon genes through a common mechanism. *J Biol Chem* **2007**, *282*, 7576-7581, doi:10.1074/jbc.M608618200.
16. Egli, A.; Santer, D.M.; O'Shea, D.; Tyrrell, D.L.; Houghton, M. The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. *Emerg Microbes Infect* **2014**, *3*, e51, doi:10.1038/emi.2014.51.
17. Sommereyns, C.; Paul, S.; Staeheli, P.; Michiels, T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. *PLoS Pathog* **2008**, *4*, e1000017, doi:10.1371/journal.ppat.1000017.
18. Lazear, H.M.; Schoggins, J.W.; Diamond, M.S. Shared and Distinct Functions of Type I and Type III Interferons. *Immunity* **2019**, *50*, 907-923, doi:10.1016/j.immuni.2019.03.025.
19. Kotenko, S.V.; Durbin, J.E. Contribution of type III interferons to antiviral immunity: location, location, location. *J Biol Chem* **2017**, *292*, 7295-7303, doi:10.1074/jbc.R117.777102.
20. Jensen, S.; Thomsen, A.R. Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion. *J Virol* **2012**, *86*, 2900-2910, doi:10.1128/JVI.05738-11.
21. Levy, D.E.; Marié, I.J.; Durbin, J.E. Induction and function of type I and III interferon in response to viral infection. *Curr Opin Virol* **2011**, *1*, 476-486, doi:10.1016/j.coviro.2011.11.001.
22. Chow, K.T.; Gale, M.; Loo, Y.M. RIG-I and Other RNA Sensors in Antiviral Immunity. *Annu Rev Immunol* **2018**, *36*, 667-694, doi:10.1146/annurev-immunol-042617-053309.
23. Belgnaoui, S.M.; Paz, S.; Hiscott, J. Orchestrating the interferon antiviral response through the mitochondrial antiviral signaling (MAVS) adapter. *Curr Opin Immunol* **2011**, *23*, 564-572, doi:10.1016/j.coi.2011.08.001.
24. Uzé, G.; Monneron, D. IL-28 and IL-29: newcomers to the interferon family. *Biochimie* **2007**, *89*, 729-734, doi:10.1016/j.biochi.2007.01.008.
25. Jilg, N.; Lin, W.; Hong, J.; Schaefer, E.A.; Wolski, D.; Meixong, J.; Goto, K.; Brisac, C.; Chusri, P.; Fusco, D.N., et al. Kinetic differences in the induction of interferon stimulated genes by interferon- α and interleukin 28B are altered by infection with hepatitis C virus. *Hepatology* **2014**, *59*, 1250-1261, doi:10.1002/hep.26653.
26. Schoggins, J.W.; Rice, C.M. Interferon-stimulated genes and their antiviral effector functions. *Curr Opin Virol* **2011**, *1*, 519-525, doi:10.1016/j.coviro.2011.10.008.
27. Tak, P.P.; Firestein, G.S. NF-kappaB: a key role in inflammatory diseases. *J Clin Invest* **2001**, *107*, 7-11, doi:10.1172/JCI11830.
28. Pahl, H.L. Activators and target genes of Rel/NF-kappaB transcription factors. *Oncogene* **1999**, *18*, 6853-6866, doi:10.1038/sj.onc.1203239.
29. Liu, T.; Zhang, L.; Joo, D.; Sun, S.C. NF- κ B signaling in inflammation. *Signal Transduct Target Ther* **2017**, *2*, doi:10.1038/sigtrans.2017.23.

30. WHO issues consensus document on the epidemiology of SARS. *Wkly Epidemiol Rec* **2003**, *78*, 373-375.
31. Drosten, C.; Günther, S.; Preiser, W.; van der Werf, S.; Brodt, H.R.; Becker, S.; Rabenau, H.; Panning, M.; Kolesnikova, L.; Fouchier, R.A., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *N Engl J Med* **2003**, *348*, 1967-1976, doi:10.1056/NEJMoa030747.
32. Ksiazek, T.G.; Erdman, D.; Goldsmith, C.S.; Zaki, S.R.; Peret, T.; Emery, S.; Tong, S.; Urbani, C.; Comer, J.A.; Lim, W., et al. A novel coronavirus associated with severe acute respiratory syndrome. *N Engl J Med* **2003**, *348*, 1953-1966, doi:10.1056/NEJMoa030781.
33. Zaki, A.M.; van Boheemen, S.; Bestebroer, T.M.; Osterhaus, A.D.; Fouchier, R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *N Engl J Med* **2012**, *367*, 1814-1820, doi:10.1056/NEJMoa1211721.
34. Fehr, A.R.; Perlman, S. Coronaviruses: an overview of their replication and pathogenesis. *Methods Mol Biol* **2015**, *1282*, 1-23, doi:10.1007/978-1-4939-2438-7_1.
35. Snijder, E.J.; Bredenbeek, P.J.; Dobbe, J.C.; Thiel, V.; Ziebuhr, J.; Poon, L.L.; Guan, Y.; Rozanov, M.; Spaan, W.J.; Gorbalenya, A.E. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. *J Mol Biol* **2003**, *331*, 991-1004.
36. Liu, D.X.; Fung, T.S.; Chong, K.K.; Shukla, A.; Hilgenfeld, R. Accessory proteins of SARS-CoV and other coronaviruses. *Antiviral Res* **2014**, *109*, 97-109, doi:10.1016/j.antiviral.2014.06.013.
37. Haagmans, B.L.; Kuiken, T.; Martina, B.E.; Fouchier, R.A.; Rimmelzwaan, G.F.; van Amerongen, G.; van Riel, D.; de Jong, T.; Itamura, S.; Chan, K.H., et al. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. *Nat Med* **2004**, *10*, 290-293, doi:10.1038/nm1001.
38. Channappanavar, R.; Fehr, A.R.; Vijay, R.; Mack, M.; Zhao, J.; Meyerholz, D.K.; Perlman, S. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. *Cell Host Microbe* **2016**, *19*, 181-193, doi:10.1016/j.chom.2016.01.007.
39. Falzarano, D.; de Wit, E.; Rasmussen, A.L.; Feldmann, F.; Okumura, A.; Scott, D.P.; Brining, D.; Bushmaker, T.; Martellaro, C.; Baseler, L., et al. Treatment with interferon- α 2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. *Nat Med* **2013**, *19*, 1313-1317, doi:10.1038/nm.3362.
40. Chan, J.F.; Yao, Y.; Yeung, M.L.; Deng, W.; Bao, L.; Jia, L.; Li, F.; Xiao, C.; Gao, H.; Yu, P., et al. Treatment With Lopinavir/Ritonavir or Interferon- β 1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. *J Infect Dis* **2015**, *212*, 1904-1913, doi:10.1093/infdis/jiv392.
41. Kumaki, Y.; Ennis, J.; Rahbar, R.; Turner, J.D.; Wandersee, M.K.; Smith, A.J.; Bailey, K.W.; Vest, Z.G.; Madsen, J.R.; Li, J.K., et al. Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model. *Antiviral Res* **2011**, *89*, 75-82, doi:10.1016/j.antiviral.2010.11.007.
42. Loutfy, M.R.; Blatt, L.M.; Siminovitch, K.A.; Ward, S.; Wolff, B.; Lho, H.; Pham, D.H.; Deif, H.; LaMere, E.A.; Chang, M., et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. *JAMA* **2003**, *290*, 3222-3228, doi:10.1001/jama.290.24.3222.
43. Omrani, A.S.; Saad, M.M.; Baig, K.; Bahloul, A.; Abdul-Matin, M.; Alaidaroos, A.Y.; Almakhlafi, G.A.; Albarrak, M.M.; Memish, Z.A.; Albarrak, A.M. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. *Lancet Infect Dis* **2014**, *14*, 1090-1095, doi:10.1016/S1473-3099(14)70920-X.

44. Shalhoub, S.; Farahat, F.; Al-Jiffri, A.; Simhairi, R.; Shamma, O.; Siddiqi, N.; Mushtaq, A. IFN- α 2a or IFN- β 1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. *J Antimicrob Chemother* **2015**, *70*, 2129-2132, doi:10.1093/jac/dkv085.
45. Al-Tawfiq, J.A.; Momattin, H.; Dib, J.; Memish, Z.A. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. *Int J Infect Dis* **2014**, *20*, 42-46, doi:10.1016/j.ijid.2013.12.003.
46. Arabi, Y.M.; Alothman, A.; Balkhy, H.H.; Al-Dawood, A.; AlJohani, S.; Al Harbi, S.; Kojan, S.; Al Jeraisy, M.; Deeb, A.M.; Assiri, A.M., et al. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon- β 1b (MIRACLE trial): study protocol for a randomized controlled trial. *Trials* **2018**, *19*, 81, doi:10.1186/s13063-017-2427-0.
47. Smits, S.L.; de Lang, A.; van den Brand, J.M.; Leijten, L.M.; van IJcken, W.F.; Eijkemans, M.J.; van Amerongen, G.; Kuiken, T.; Andeweg, A.C.; Osterhaus, A.D., et al. Exacerbated innate host response to SARS-CoV in aged non-human primates. *PLoS Pathog* **2010**, *6*, e1000756, doi:10.1371/journal.ppat.1000756.
48. Yu, S.Y.; Hu, Y.W.; Liu, X.Y.; Xiong, W.; Zhou, Z.T.; Yuan, Z.H. Gene expression profiles in peripheral blood mononuclear cells of SARS patients. *World J Gastroenterol* **2005**, *11*, 5037-5043, doi:10.3748/wjg.v11.i32.5037.
49. Reghunathan, R.; Jayapal, M.; Hsu, L.Y.; Chng, H.H.; Tai, D.; Leung, B.P.; Melendez, A.J. Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome. *BMC Immunol* **2005**, *6*, 2, doi:10.1186/1471-2172-6-2.
50. Faure, E.; Poissy, J.; Goffard, A.; Fournier, C.; Kipnis, E.; Titecat, M.; Bortolotti, P.; Martinez, L.; Dubucquoi, S.; Dessein, R., et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? *PLoS One* **2014**, *9*, e88716, doi:10.1371/journal.pone.0088716.
51. Hogan, R.J.; Gao, G.; Rowe, T.; Bell, P.; Flieder, D.; Paragas, J.; Kobinger, G.P.; Wivel, N.A.; Crystal, R.G.; Boyer, J., et al. Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1. *J Virol* **2004**, *78*, 11416-11421, doi:10.1128/JVI.78.20.11416-11421.2004.
52. Frieman, M.B.; Chen, J.; Morrison, T.E.; Whitmore, A.; Funkhouser, W.; Ward, J.M.; Lamirande, E.W.; Roberts, A.; Heise, M.; Subbarao, K., et al. SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. *PLoS Pathog* **2010**, *6*, e1000849, doi:10.1371/journal.ppat.1000849.
53. Mordstein, M.; Neugebauer, E.; Ditt, V.; Jessen, B.; Rieger, T.; Falcone, V.; Sorgeloos, F.; Ehl, S.; Mayer, D.; Kochs, G., et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. *J Virol* **2010**, *84*, 5670-5677, doi:10.1128/JVI.00272-10.
54. Mahlaköiv, T.; Ritz, D.; Mordstein, M.; DeDiego, M.L.; Enjuanes, L.; Müller, M.A.; Drosten, C.; Staeheli, P. Combined action of type I and type III interferon restricts initial replication of severe acute respiratory syndrome coronavirus in the lung but fails to inhibit systemic virus spread. *J Gen Virol* **2012**, *93*, 2601-2605, doi:10.1099/vir.0.046284-0.
55. Totura, A.L.; Whitmore, A.; Agnihothram, S.; Schäfer, A.; Katze, M.G.; Heise, M.T.; Baric, R.S. Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection. *MBio* **2015**, *6*, e00638-00615, doi:10.1128/mBio.00638-15.
56. Sheahan, T.; Morrison, T.E.; Funkhouser, W.; Uematsu, S.; Akira, S.; Baric, R.S.; Heise, M.T. MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. *PLoS Pathog* **2008**, *4*, e1000240, doi:10.1371/journal.ppat.1000240.

57. Zhao, J.; Li, K.; Wohlford-Lenane, C.; Agnihothram, S.S.; Fett, C.; Gale, M.J.; Baric, R.S.; Enjuanes, L.; Gallagher, T.; McCray, P.B., et al. Rapid generation of a mouse model for Middle East respiratory syndrome. *Proc Natl Acad Sci U S A* **2014**, *111*, 4970-4975, doi:10.1073/pnas.1323279111.
58. Nicholls, J.M.; Poon, L.L.; Lee, K.C.; Ng, W.F.; Lai, S.T.; Leung, C.Y.; Chu, C.M.; Hui, P.K.; Mak, K.L.; Lim, W., et al. Lung pathology of fatal severe acute respiratory syndrome. *Lancet* **2003**, *361*, 1773-1778.
59. Lo, A.W.; Tang, N.L.; To, K.F. How the SARS coronavirus causes disease: host or organism? *J Pathol* **2006**, *208*, 142-151, doi:10.1002/path.1897.
60. Wong, C.K.; Lam, C.W.; Wu, A.K.; Ip, W.K.; Lee, N.L.; Chan, I.H.; Lit, L.C.; Hui, D.S.; Chan, M.H.; Chung, S.S., et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. *Clin Exp Immunol* **2004**, *136*, 95-103, doi:10.1111/j.1365-2249.2004.02415.x.
61. Chien, J.Y.; Hsueh, P.R.; Cheng, W.C.; Yu, C.J.; Yang, P.C. Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome. *Respirology* **2006**, *11*, 715-722, doi:10.1111/j.1440-1843.2006.00942.x.
62. Huang, K.J.; Su, I.J.; Theron, M.; Wu, Y.C.; Lai, S.K.; Liu, C.C.; Lei, H.Y. An interferon-gamma-related cytokine storm in SARS patients. *J Med Virol* **2005**, *75*, 185-194, doi:10.1002/jmv.20255.
63. Cameron, M.J.; Ran, L.; Xu, L.; Danesh, A.; Bermejo-Martin, J.F.; Cameron, C.M.; Muller, M.P.; Gold, W.L.; Richardson, S.E.; Poutanen, S.M., et al. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. *J Virol* **2007**, *81*, 8692-8706, doi:10.1128/JVI.00527-07.
64. Min, C.K.; Cheon, S.; Ha, N.Y.; Sohn, K.M.; Kim, Y.; Aigerim, A.; Shin, H.M.; Choi, J.Y.; Inn, K.S.; Kim, J.H., et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. *Sci Rep* **2016**, *6*, 25359, doi:10.1038/srep25359.
65. Kim, E.S.; Choe, P.G.; Park, W.B.; Oh, H.S.; Kim, E.J.; Nam, E.Y.; Na, S.H.; Kim, M.; Song, K.H.; Bang, J.H., et al. Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection. *J Korean Med Sci* **2016**, *31*, 1717-1725, doi:10.3346/jkms.2016.31.11.1717.
66. Roberts, A.; Deming, D.; Paddock, C.D.; Cheng, A.; Yount, B.; Vogel, L.; Herman, B.D.; Sheahan, T.; Heise, M.; Genrich, G.L., et al. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. *PLoS Pathog* **2007**, *3*, e5, doi:10.1371/journal.ppat.0030005.
67. DeDiego, M.L.; Nieto-Torres, J.L.; Regla-Nava, J.A.; Jimenez-Guardeño, J.M.; Fernandez-Delgado, R.; Fett, C.; Castaño-Rodríguez, C.; Perlman, S.; Enjuanes, L. Inhibition of NF- κ B-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. *J Virol* **2014**, *88*, 913-924, doi:10.1128/JVI.02576-13.
68. de Wilde, A.H.; Raj, V.S.; Oudshoorn, D.; Bestebroer, T.M.; van Nieuwkoop, S.; Limpens, R.W.; Posthuma, C.C.; van der Meer, Y.; Bárcena, M.; Haagmans, B.L., et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon- α treatment. *J Gen Virol* **2013**, *94*, 1749-1760, doi:10.1099/vir.0.052910-0.
69. Zielecki, F.; Weber, M.; Eickmann, M.; Spiegelberg, L.; Zaki, A.M.; Matrosovich, M.; Becker, S.; Weber, F. Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus. *J Virol* **2013**, *87*, 5300-5304, doi:10.1128/JVI.03496-12.
70. Nieto-Torres, J.L.; DeDiego, M.L.; Verdía-Báguena, C.; Jimenez-Guardeño, J.M.; Regla-Nava, J.A.; Fernandez-Delgado, R.; Castaño-Rodríguez, C.; Alcaraz, A.; Torres, J.; Aguilera, V.M., et al. Severe acute respiratory syndrome coronavirus envelope protein ion channel activity

- promotes virus fitness and pathogenesis. *PLoS Pathog* **2014**, *10*, e1004077, doi:10.1371/journal.ppat.1004077.
71. Kopecky-Bromberg, S.A.; Martínez-Sobrido, L.; Frieman, M.; Baric, R.A.; Palese, P. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. *J Virol* **2007**, *81*, 548-557, doi:10.1128/JVI.01782-06.
 72. Dediego, M.L.; Pewe, L.; Alvarez, E.; Rejas, M.T.; Perlman, S.; Enjuanes, L. Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice. *Virology* **2008**, *376*, 379-389, doi:10.1016/j.virol.2008.03.005.
 73. Zhao, J.; Falcón, A.; Zhou, H.; Netland, J.; Enjuanes, L.; Pérez Breña, P.; Perlman, S. Severe acute respiratory syndrome coronavirus protein 6 is required for optimal replication. *J Virol* **2009**, *83*, 2368-2373, doi:10.1128/JVI.02371-08.
 74. Yount, B.; Roberts, R.S.; Sims, A.C.; Deming, D.; Frieman, M.B.; Sparks, J.; Denison, M.R.; Davis, N.; Baric, R.S. Severe acute respiratory syndrome coronavirus group-specific open reading frames encode nonessential functions for replication in cell cultures and mice. *J Virol* **2005**, *79*, 14909-14922, doi:10.1128/JVI.79.23.14909-14922.2005.
 75. Schaecher, S.R.; Stabenow, J.; Oberle, C.; Schriewer, J.; Buller, R.M.; Sagartz, J.E.; Pekosz, A. An immunosuppressed Syrian golden hamster model for SARS-CoV infection. *Virology* **2008**, *380*, 312-321, doi:10.1016/j.virol.2008.07.026.
 76. Cockrell, A.S.; Yount, B.L.; Scobey, T.; Jensen, K.; Douglas, M.; Beall, A.; Tang, X.C.; Marasco, W.A.; Heise, M.T.; Baric, R.S. A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. *Nat Microbiol* **2016**, *2*, 16226, doi:10.1038/nmicrobiol.2016.226.
 77. Menachery, V.D.; Mitchell, H.D.; Cockrell, A.S.; Gralinski, L.E.; Yount, B.L.; Graham, R.L.; McAnarney, E.T.; Douglas, M.G.; Scobey, T.; Beall, A., et al. MERS-CoV Accessory ORFs Play Key Role for Infection and Pathogenesis. *MBio* **2017**, *8*, doi:10.1128/mBio.00665-17.
 78. Thornbrough, J.M.; Jha, B.K.; Yount, B.; Goldstein, S.A.; Li, Y.; Elliott, R.; Sims, A.C.; Baric, R.S.; Silverman, R.H.; Weiss, S.R. Middle East Respiratory Syndrome Coronavirus NS4b Protein Inhibits Host RNase L Activation. *MBio* **2016**, *7*, e00258, doi:10.1128/mBio.00258-16.
 79. Frieman, M.; Yount, B.; Heise, M.; Kopecky-Bromberg, S.A.; Palese, P.; Baric, R.S. Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. *J Virol* **2007**, *81*, 9812-9824, doi:10.1128/JVI.01012-07.
 80. Fehr, A.R.; Channappanavar, R.; Jankevicius, G.; Fett, C.; Zhao, J.; Athmer, J.; Meyerholz, D.K.; Ahel, I.; Perlman, S. The Conserved Coronavirus Macrodomain Promotes Virulence and Suppresses the Innate Immune Response during Severe Acute Respiratory Syndrome Coronavirus Infection. *MBio* **2016**, *7*, doi:10.1128/mBio.01721-16.
 81. Mielech, A.M.; Chen, Y.; Mesecar, A.D.; Baker, S.C. Nidovirus papain-like proteases: multifunctional enzymes with protease, deubiquitinating and deISGylating activities. *Virus Res* **2014**, *194*, 184-190, doi:10.1016/j.virusres.2014.01.025.
 82. Menachery, V.D.; Yount, B.L.; Josset, L.; Gralinski, L.E.; Scobey, T.; Agnihothram, S.; Katze, M.G.; Baric, R.S. Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2'-O-methyltransferase activity. *J Virol* **2014**, *88*, 4251-4264, doi:10.1128/JVI.03571-13.
 83. Menachery, V.D.; Gralinski, L.E.; Mitchell, H.D.; Dinno, K.H.; Leist, S.R.; Yount, B.L.; Graham, R.L.; McAnarney, E.T.; Stratton, K.G.; Cockrell, A.S., et al. Middle East Respiratory Syndrome Coronavirus Nonstructural Protein 16 Is Necessary for Interferon Resistance and Viral Pathogenesis. *mSphere* **2017**, *2*, doi:10.1128/mSphere.00346-17.

84. Morales, L.; Oliveros, J.C.; Fernandez-Delgado, R.; tenOever, B.R.; Enjuanes, L.; Sola, I. SARS-CoV-Encoded Small RNAs Contribute to Infection-Associated Lung Pathology. *Cell Host Microbe* **2017**, *21*, 344-355, doi:10.1016/j.chom.2017.01.015.
85. Cunha, R.V.D.; Trinta, K.S. Chikungunya virus: clinical aspects and treatment - A Review. *Mem Inst Oswaldo Cruz* **2017**, *112*, 523-531, doi:10.1590/0074-02760170044.
86. Galán-Huerta, K.A.; Rivas-Estilla, A.M.; Fernández-Salas, I.; Farfan-Ale, J.A.; Ramos-Jiménez, J. Chikungunya virus: A general overview. *Medicina Universitaria* **2015**, *17*, 175-183, doi:<https://doi.org/10.1016/j.rmu.2015.06.001>.
87. Leung, J.Y.; Ng, M.M.; Chu, J.J. Replication of alphaviruses: a review on the entry process of alphaviruses into cells. *Adv Virol* **2011**, *2011*, 249640, doi:10.1155/2011/249640.
88. Schilte, C.; Couderc, T.; Chretien, F.; Sourisseau, M.; Gangneux, N.; Guivel-Benhassine, F.; Kraxner, A.; Tschopp, J.; Higgs, S.; Michault, A., et al. Type I IFN controls chikungunya virus via its action on nonhematopoietic cells. *J Exp Med* **2010**, *207*, 429-442, doi:10.1084/jem.20090851.
89. Gardner, J.; Anraku, I.; Le, T.T.; Larcher, T.; Major, L.; Roques, P.; Schroder, W.A.; Higgs, S.; Suhrbier, A. Chikungunya virus arthritis in adult wild-type mice. *J Virol* **2010**, *84*, 8021-8032, doi:10.1128/JVI.02603-09.
90. Labadie, K.; Larcher, T.; Joubert, C.; Mannioui, A.; Delache, B.; Brochard, P.; Guigand, L.; Dubreil, L.; Lebon, P.; Verrier, B., et al. Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. *J Clin Invest* **2010**, *120*, 894-906, doi:10.1172/JCI40104.
91. Chow, A.; Her, Z.; Ong, E.K.; Chen, J.M.; Dimatatac, F.; Kwek, D.J.; Barkham, T.; Yang, H.; Rénia, L.; Leo, Y.S., et al. Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor. *J Infect Dis* **2011**, *203*, 149-157, doi:10.1093/infdis/jiq042.
92. Ng, L.F.; Chow, A.; Sun, Y.J.; Kwek, D.J.; Lim, P.L.; Dimatatac, F.; Ng, L.C.; Ooi, E.E.; Choo, K.H.; Her, Z., et al. IL-1beta, IL-6, and RANTES as biomarkers of Chikungunya severity. *PLoS One* **2009**, *4*, e4261, doi:10.1371/journal.pone.0004261.
93. Teng, T.S.; Kam, Y.W.; Lee, B.; Hapuarachchi, H.C.; Wimal, A.; Ng, L.C.; Ng, L.F. A Systematic Meta-analysis of Immune Signatures in Patients With Acute Chikungunya Virus Infection. *J Infect Dis* **2015**, *211*, 1925-1935, doi:10.1093/infdis/jiv049.
94. Messaoudi, I.; Vomasse, J.; Totonchy, T.; Kreklywich, C.N.; Haberthur, K.; Springgay, L.; Brien, J.D.; Diamond, M.S.; Defilippis, V.R.; Streblow, D.N. Chikungunya virus infection results in higher and persistent viral replication in aged rhesus macaques due to defects in anti-viral immunity. *PLoS Negl Trop Dis* **2013**, *7*, e2343, doi:10.1371/journal.pntd.0002343.
95. Ng, L.F.P. Immunopathology of Chikungunya Virus Infection: Lessons Learned from Patients and Animal Models. *Annu Rev Virol* **2017**, *4*, 413-427, doi:10.1146/annurev-virology-101416-041808.
96. Her, Z.; Teng, T.S.; Tan, J.J.; Teo, T.H.; Kam, Y.W.; Lum, F.M.; Lee, W.W.; Gabriel, C.; Melchioti, R.; Andiappan, A.K., et al. Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virus-specific neutralizing antibody response. *EMBO Mol Med* **2015**, *7*, 24-41, doi:10.15252/emmm.201404459.
97. Rudd, P.A.; Wilson, J.; Gardner, J.; Larcher, T.; Babarit, C.; Le, T.T.; Anraku, I.; Kumagai, Y.; Loo, Y.M.; Gale, M., et al. Interferon response factors 3 and 7 protect against Chikungunya virus hemorrhagic fever and shock. *J Virol* **2012**, *86*, 9888-9898, doi:10.1128/JVI.00956-12.
98. Gardner, C.L.; Burke, C.W.; Higgs, S.T.; Klimstra, W.B.; Ryman, K.D. Interferon-alpha/beta deficiency greatly exacerbates arthritogenic disease in mice infected with wild-type chikungunya virus but not with the cell culture-adapted live-attenuated 181/25 vaccine candidate. *Virology* **2012**, *425*, 103-112, doi:10.1016/j.virol.2011.12.020.

99. Couderc, T.; Chrétien, F.; Schilte, C.; Disson, O.; Brigitte, M.; Guivel-Benhassine, F.; Touret, Y.; Barau, G.; Cayet, N.; Schuffenecker, I., et al. A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. *PLoS Pathog* **2008**, *4*, e29, doi:10.1371/journal.ppat.0040029.
100. Teng, T.S.; Foo, S.S.; Simamarta, D.; Lum, F.M.; Teo, T.H.; Lulla, A.; Yeo, N.K.; Koh, E.G.; Chow, A.; Leo, Y.S., et al. Viperin restricts chikungunya virus replication and pathology. *J Clin Invest* **2012**, *122*, 4447-4460, doi:10.1172/JCI63120.
101. Poddar, S.; Hyde, J.L.; Gorman, M.J.; Farzan, M.; Diamond, M.S. The Interferon-Stimulated Gene IFITM3 Restricts Infection and Pathogenesis of Arthritogenic and Encephalitic Alphaviruses. *J Virol* **2016**, *90*, 8780-8794, doi:10.1128/JVI.00655-16.
102. Clavarino, G.; Cláudio, N.; Couderc, T.; Dalet, A.; Judith, D.; Camosseto, V.; Schmidt, E.K.; Wenger, T.; Lecuit, M.; Gatti, E., et al. Induction of GADD34 is necessary for dsRNA-dependent interferon- β production and participates in the control of Chikungunya virus infection. *PLoS Pathog* **2012**, *8*, e1002708, doi:10.1371/journal.ppat.1002708.
103. Werneke, S.W.; Schilte, C.; Rohatgi, A.; Monte, K.J.; Michault, A.; Arenzana-Seisdedos, F.; Vanlandingham, D.L.; Higgs, S.; Fontanet, A.; Albert, M.L., et al. ISG15 is critical in the control of Chikungunya virus infection independent of UBE1L mediated conjugation. *PLoS Pathog* **2011**, *7*, e1002322, doi:10.1371/journal.ppat.1002322.
104. Hawman, D.W.; Stoermer, K.A.; Montgomery, S.A.; Pal, P.; Oko, L.; Diamond, M.S.; Morrison, T.E. Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response. *J Virol* **2013**, *87*, 13878-13888, doi:10.1128/JVI.02666-13.
105. Fros, J.J.; Pijlman, G.P. Alphavirus Infection: Host Cell Shut-Off and Inhibition of Antiviral Responses. *Viruses* **2016**, *8*, doi:10.3390/v8060166.
106. White, L.K.; Sali, T.; Alvarado, D.; Gatti, E.; Pierre, P.; Streblow, D.; Defilippis, V.R. Chikungunya virus induces IPS-1-dependent innate immune activation and protein kinase R-independent translational shutoff. *J Virol* **2011**, *85*, 606-620, doi:10.1128/JVI.00767-10.
107. Frolova, E.I.; Fayzuln, R.Z.; Cook, S.H.; Griffin, D.E.; Rice, C.M.; Frolov, I. Roles of nonstructural protein nsP2 and Alpha/Beta interferons in determining the outcome of Sindbis virus infection. *J Virol* **2002**, *76*, 11254-11264, doi:10.1128/jvi.76.22.11254-11264.2002.
108. Chan, Y.H.; Teo, T.H.; Utt, A.; Tan, J.J.; Amrun, S.N.; Abu Bakar, F.; Yee, W.X.; Becht, E.; Lee, C.Y.P.; Lee, B., et al. Mutating chikungunya virus non-structural protein produces potent live-attenuated vaccine candidate. *EMBO Molecular Medicine* **2019**, e10092, doi:10.15252/emmm.201810092.
109. Fernandez-Garcia, M.D.; Mazzon, M.; Jacobs, M.; Amara, A. Pathogenesis of flavivirus infections: using and abusing the host cell. *Cell Host Microbe* **2009**, *5*, 318-328, doi:10.1016/j.chom.2009.04.001.
110. Mustafa, M.S.; Rasotgi, V.; Jain, S.; Gupta, V. Discovery of fifth serotype of dengue virus (DENV-5): A new public health dilemma in dengue control. *Med J Armed Forces India* **2015**, *71*, 67-70, doi:10.1016/j.mjafi.2014.09.011.
111. Guzman, M.G.; Harris, E. Dengue. *Lancet* **2015**, *385*, 453-465, doi:10.1016/S0140-6736(14)60572-9.
112. Paixão, E.S.; Teixeira, M.G.; Rodrigues, L.C. Zika, chikungunya and dengue: the causes and threats of new and re-emerging arboviral diseases. *BMJ Glob Health* **2018**, *3*, e000530, doi:10.1136/bmjgh-2017-000530.
113. Noorbakhsh, F.; Abdolmohammadi, K.; Fatahi, Y.; Dalili, H.; Rasoolinejad, M.; Rezaei, F.; Salehi-Vaziri, M.; Shafiei-Jandaghi, N.Z.; Gooshki, E.S.; Zaim, M., et al. Zika Virus Infection, Basic and Clinical Aspects: A Review Article. *Iran J Public Health* **2019**, *48*, 20-31.
114. da Silva, M.H.M.; Moises, R.N.C.; Alves, B.E.B.; Pereira, H.W.B.; de Paiva, A.A.P.; Morais, I.C.; Nascimento, Y.M.; Monteiro, J.D.; de Souto, J.T.; Nascimento, M.S.L., et al. Innate immune

- response in patients with acute Zika virus infection. *Med Microbiol Immunol* **2019**, doi:10.1007/s00430-019-00588-8.
115. Lum, F.M.; Lye, D.C.B.; Tan, J.J.L.; Lee, B.; Chia, P.Y.; Chua, T.K.; Amrun, S.N.; Kam, Y.W.; Yee, W.X.; Ling, W.P., et al. Longitudinal Study of Cellular and Systemic Cytokine Signatures to Define the Dynamics of a Balanced Immune Environment During Disease Manifestation in Zika Virus-Infected Patients. *J Infect Dis* **2018**, *218*, 814-824, doi:10.1093/infdis/jiy225.
 116. Kam, Y.W.; Leite, J.A.; Lum, F.M.; Tan, J.J.L.; Lee, B.; Judice, C.C.; Teixeira, D.A.T.; Andreato-Santos, R.; Vinolo, M.A.; Angerami, R., et al. Specific Biomarkers Associated With Neurological Complications and Congenital Central Nervous System Abnormalities From Zika Virus-Infected Patients in Brazil. *J Infect Dis* **2017**, *216*, 172-181, doi:10.1093/infdis/jix261.
 117. Her, Z.; Kam, Y.W.; Gan, V.C.; Lee, B.; Thein, T.L.; Tan, J.J.; Lee, L.K.; Fink, K.; Lye, D.C.; Rénia, L., et al. Severity of Plasma Leakage Is Associated With High Levels of Interferon γ -Inducible Protein 10, Hepatocyte Growth Factor, Matrix Metalloproteinase 2 (MMP-2), and MMP-9 During Dengue Virus Infection. *J Infect Dis* **2017**, *215*, 42-51, doi:10.1093/infdis/jiw494.
 118. Zhao, L.; Huang, X.; Hong, W.; Qiu, S.; Wang, J.; Yu, L.; Zeng, Y.; Tan, X.; Zhang, F. Slow resolution of inflammation in severe adult dengue patients. *BMC Infect Dis* **2016**, *16*, 291, doi:10.1186/s12879-016-1596-x.
 119. Pandey, N.; Jain, A.; Garg, R.K.; Kumar, R.; Agrawal, O.P.; Lakshmana Rao, P.V. Serum levels of IL-8, IFN γ , IL-10, and TGF β and their gene expression levels in severe and non-severe cases of dengue virus infection. *Arch Virol* **2015**, *160*, 1463-1475, doi:10.1007/s00705-015-2410-6.
 120. Malavige, G.N.; Gomes, L.; Alles, L.; Chang, T.; Salimi, M.; Fernando, S.; Nanayakkara, K.D.; Jayaratne, S.; Ogg, G.S. Serum IL-10 as a marker of severe dengue infection. *BMC Infect Dis* **2013**, *13*, 341, doi:10.1186/1471-2334-13-341.
 121. Butthep, P.; Chunhakan, S.; Yoksan, S.; Tangnararatchakit, K.; Chuansumrit, A. Alteration of cytokines and chemokines during febrile episodes associated with endothelial cell damage and plasma leakage in dengue hemorrhagic fever. *Pediatr Infect Dis J* **2012**, *31*, e232-238, doi:10.1097/INF.0b013e31826fd456.
 122. Rossi, S.L.; Tesh, R.B.; Azar, S.R.; Muruato, A.E.; Hanley, K.A.; Auguste, A.J.; Langsjoen, R.M.; Paessler, S.; Vasilakis, N.; Weaver, S.C. Characterization of a Novel Murine Model to Study Zika Virus. *Am J Trop Med Hyg* **2016**, *94*, 1362-1369, doi:10.4269/ajtmh.16-0111.
 123. Dowall, S.D.; Graham, V.A.; Rayner, E.; Atkinson, B.; Hall, G.; Watson, R.J.; Bosworth, A.; Bonney, L.C.; Kitchen, S.; Hewson, R. A Susceptible Mouse Model for Zika Virus Infection. *PLoS Negl Trop Dis* **2016**, *10*, e0004658, doi:10.1371/journal.pntd.0004658.
 124. Aliota, M.T.; Caine, E.A.; Walker, E.C.; Larkin, K.E.; Camacho, E.; Osorio, J.E. Characterization of Lethal Zika Virus Infection in AG129 Mice. *PLoS Negl Trop Dis* **2016**, *10*, e0004682, doi:10.1371/journal.pntd.0004682.
 125. Shresta, S.; Kyle, J.L.; Snider, H.M.; Basavapatna, M.; Beatty, P.R.; Harris, E. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. *J Virol* **2004**, *78*, 2701-2710, doi:10.1128/jvi.78.6.2701-2710.2004.
 126. Johnson, A.J.; Roehrig, J.T. New mouse model for dengue virus vaccine testing. *J Virol* **1999**, *73*, 783-786.
 127. Shresta, S.; Sharar, K.L.; Prigozhin, D.M.; Beatty, P.R.; Harris, E. Murine model for dengue virus-induced lethal disease with increased vascular permeability. *J Virol* **2006**, *80*, 10208-10217, doi:10.1128/JVI.00062-06.
 128. Orozco, S.; Schmid, M.A.; Parameswaran, P.; Lachica, R.; Henn, M.R.; Beatty, R.; Harris, E. Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in

- the alpha/beta interferon receptor. *J Gen Virol* **2012**, *93*, 2152-2157, doi:10.1099/vir.0.045088-0.
129. Smith, D.R.; Hollidge, B.; Daye, S.; Zeng, X.; Blancett, C.; Kuszpit, K.; Bocan, T.; Koehler, J.W.; Coyne, S.; Minogue, T., et al. Neuropathogenesis of Zika Virus in a Highly Susceptible Immunocompetent Mouse Model after Antibody Blockade of Type I Interferon. *PLoS Negl Trop Dis* **2017**, *11*, e0005296, doi:10.1371/journal.pntd.0005296.
130. Khan, S.; Woodruff, E.M.; Trapecar, M.; Fontaine, K.A.; Ezaki, A.; Borbet, T.C.; Ott, M.; Sanjabi, S. Dampened antiviral immunity to intravaginal exposure to RNA viral pathogens allows enhanced viral replication. *J Exp Med* **2016**, *213*, 2913-2929, doi:10.1084/jem.20161289.
131. Lazear, H.M.; Govero, J.; Smith, A.M.; Platt, D.J.; Fernandez, E.; Miner, J.J.; Diamond, M.S. A Mouse Model of Zika Virus Pathogenesis. *Cell Host Microbe* **2016**, *19*, 720-730, doi:10.1016/j.chom.2016.03.010.
132. Christofferson, R.C.; McCracken, M.K.; Johnson, A.M.; Chisenhall, D.M.; Mores, C.N. Development of a transmission model for dengue virus. *Virology* **2013**, *10*, 127, doi:10.1186/1743-422X-10-127.
133. Piret, J.; Carbonneau, J.; Rhéaume, C.; Baz, M.; Boivin, G. Predominant role of IPS-1 over TRIF adaptor proteins in early innate immune response against Zika virus in mice. *J Gen Virol* **2018**, *99*, 209-218, doi:10.1099/jgv.0.000992.
134. Perry, S.T.; Prestwood, T.R.; Lada, S.M.; Benedict, C.A.; Shresta, S. Cardif-mediated signaling controls the initial innate response to dengue virus in vivo. *J Virol* **2009**, *83*, 8276-8281, doi:10.1128/JVI.00365-09.
135. Chen, S.T.; Lin, Y.L.; Huang, M.T.; Wu, M.F.; Cheng, S.C.; Lei, H.Y.; Lee, C.K.; Chiou, T.W.; Wong, C.H.; Hsieh, S.L. CLEC5A is critical for dengue-virus-induced lethal disease. *Nature* **2008**, *453*, 672-676, doi:10.1038/nature07013.
136. Sariol, C.A.; Martínez, M.I.; Rivera, F.; Rodríguez, I.V.; Pantoja, P.; Abel, K.; Arana, T.; Giavedoni, L.; Hodara, V.; White, L.J., et al. Decreased dengue replication and an increased anti-viral humoral response with the use of combined Toll-like receptor 3 and 7/8 agonists in macaques. *PLoS One* **2011**, *6*, e19323, doi:10.1371/journal.pone.0019323.
137. Weisblum, Y.; Oiknine-Djian, E.; Vorontsov, O.M.; Haimov-Kochman, R.; Zakay-Rones, Z.; Meir, K.; Shveiky, D.; Elgavish, S.; Nevo, Y.; Roseman, M., et al. Zika Virus Infects Early- and Midgestation Human Maternal Decidual Tissues, Inducing Distinct Innate Tissue Responses in the Maternal-Fetal Interface. *J Virol* **2017**, *91*, doi:10.1128/JVI.01905-16.
138. Chen, J.; Liang, Y.; Yi, P.; Xu, L.; Hawkins, H.K.; Rossi, S.L.; Soong, L.; Cai, J.; Menon, R.; Sun, J. Outcomes of Congenital Zika Disease Depend on Timing of Infection and Maternal-Fetal Interferon Action. *Cell Rep* **2017**, *21*, 1588-1599, doi:10.1016/j.celrep.2017.10.059.
139. Miner, J.J.; Cao, B.; Govero, J.; Smith, A.M.; Fernandez, E.; Cabrera, O.H.; Garber, C.; Noll, M.; Klein, R.S.; Noguchi, K.K., et al. Zika Virus Infection during Pregnancy in Mice Causes Placental Damage and Fetal Demise. *Cell* **2016**, *165*, 1081-1091, doi:10.1016/j.cell.2016.05.008.
140. Yockey, L.J.; Jurado, K.A.; Arora, N.; Millet, A.; Rakib, T.; Milano, K.M.; Hastings, A.K.; Fikrig, E.; Kong, Y.; Horvath, T.L., et al. Type I interferons instigate fetal demise after Zika virus infection. *Sci Immunol* **2018**, *3*, doi:10.1126/sciimmunol.aao1680.
141. Bayer, A.; Lennemann, N.J.; Ouyang, Y.; Bramley, J.C.; Morosky, S.; Marques, E.T.; Cherry, S.; Sadovskiy, Y.; Coyne, C.B. Type III Interferons Produced by Human Placental Trophoblasts Confer Protection against Zika Virus Infection. *Cell Host Microbe* **2016**, *19*, 705-712, doi:10.1016/j.chom.2016.03.008.
142. Corry, J.; Arora, N.; Good, C.A.; Sadovskiy, Y.; Coyne, C.B. Organotypic models of type III interferon-mediated protection from Zika virus infections at the maternal-fetal interface. *Proc Natl Acad Sci U S A* **2017**, *114*, 9433-9438, doi:10.1073/pnas.1707513114.

143. Jagger, B.W.; Miner, J.J.; Cao, B.; Arora, N.; Smith, A.M.; Kovacs, A.; Mysorekar, I.U.; Coyne, C.B.; Diamond, M.S. Gestational Stage and IFN- λ Signaling Regulate ZIKV Infection In Utero. *Cell Host Microbe* **2017**, *22*, 366-376.e363, doi:10.1016/j.chom.2017.08.012.
144. Beatty, P.R.; Puerta-Guardo, H.; Killingbeck, S.S.; Glasner, D.R.; Hopkins, K.; Harris, E. Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. *Sci Transl Med* **2015**, *7*, 304ra141, doi:10.1126/scitranslmed.aaa3787.
145. Ashour, J.; Laurent-Rolle, M.; Shi, P.Y.; García-Sastre, A. NS5 of dengue virus mediates STAT2 binding and degradation. *J Virol* **2009**, *83*, 5408-5418, doi:10.1128/JVI.02188-08.
146. Ashour, J.; Morrison, J.; Laurent-Rolle, M.; Belicha-Villanueva, A.; Plumlee, C.R.; Bernal-Rubio, D.; Williams, K.L.; Harris, E.; Fernandez-Sesma, A.; Schindler, C., et al. Mouse STAT2 restricts early dengue virus replication. *Cell Host Microbe* **2010**, *8*, 410-421, doi:10.1016/j.chom.2010.10.007.
147. Ding, Q.; Gaska, J.M.; Douam, F.; Wei, L.; Kim, D.; Balev, M.; Heller, B.; Ploss, A. Species-specific disruption of STING-dependent antiviral cellular defenses by the Zika virus NS2B3 protease. *Proc Natl Acad Sci U S A* **2018**, *115*, E6310-E6318, doi:10.1073/pnas.1803406115.
148. Zheng, Y.; Liu, Q.; Wu, Y.; Ma, L.; Zhang, Z.; Liu, T.; Jin, S.; She, Y.; Li, Y.P.; Cui, J. Zika virus elicits inflammation to evade antiviral response by cleaving cGAS via NS1-caspase-1 axis. *EMBO J* **2018**, *37*, doi:10.15252/embj.201899347.
149. Xia, H.; Luo, H.; Shan, C.; Muruato, A.E.; Nunes, B.T.D.; Medeiros, D.B.A.; Zou, J.; Xie, X.; Giraldo, M.I.; Vasconcelos, P.F.C., et al. An evolutionary NS1 mutation enhances Zika virus evasion of host interferon induction. *Nat Commun* **2018**, *9*, 414, doi:10.1038/s41467-017-02816-2.